H.C. Wainwright analyst Arthur He raised the firm’s price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares. The company this morning announced positive results from the induction period of its ongoing Phase 2b REZOLVE-AD study evaluating rezpegaldesleukin in patients with moderate to-severe atopic dermatitis, the analyst tells investors in a research note. Citing the drug’s “highly differentiated mechanism of action” compared to currently approved therapies, H.C. Wainwright believes rezpeg “has the potential to reshape the treatment landscape” for atopic dermatitis. The firm expects to see further improvement in efficacy in the next clinical data update when the 36-week maintenance data is expected to be reported in Q1 of 2026. Nektar says a “paradigm-shifting” atopic dermatitis drug “has arrived.” The stock in midday trading is up 134%, or $12.82, to $22.36.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar price target raised to $120 from $6.50 at H.C. Wainwright
- Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today?
- Nektar jumps 130% to $21.90 after atopic dermatitis study success
- Nektar Therapeutics Announces Positive Phase 2b Trial Results
- Nektar’s rezpegaldesleukin meets endpoints in Phase 2b atopic dermatitis trial